

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天 辰 生 物

LongBio Pharma (Suzhou) Co., Ltd.

天辰生物醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1779)

**VOLUNTARY ANNOUNCEMENT
A PHASE III CLINICAL TRIAL OF LP-003
FOR THE INDICATION OF SEASONAL AR
MET PRIMARY ENDPOINTS**

This announcement is made by LongBio Pharma (Suzhou) Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that a phase III clinical trial of LP-003 for seasonal allergic rhinitis (“**AR**”) has met the pre-specified primary endpoints and the results are highly statistically and clinically significant.

AR is a non-infectious chronic inflammatory disease of the nasal mucosa, primarily driven by IgE after exposure to allergens in atopic individuals. It is characterized by nasal inflammation caused by allergens such as pollen, dust mites, animal dander and mold. AR is often associated with other allergic diseases, such as asthma and conjunctivitis. The main symptoms of AR include sneezing, runny nose, nasal congestion, and itching, and depending on the allergens involved, the symptoms may be seasonal or perennial. AR affects 10% to 20% of the global population and has become a major chronic respiratory inflammatory disease, severely impacting the quality of life and socioeconomic conditions of patients.

Phase III clinical trial of LP-003 for the indication of seasonal AR is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study in China to compare LP-003 with placebo for the treatment of moderate-to-severe seasonal AR that is inadequately controlled by SoC treatment. We have enrolled 546 patients, who are randomly divided into 2 groups and receive either 100 mg LP-003 injection once every 4 weeks (Q4W) or placebo once every 4 weeks (Q4W). Patients with seasonal AR who meet the diagnostic criteria of the “Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in China (2022, revised edition)” and have not achieved satisfactory results with standard treatment are included. The main exclusion criterion is patients with concurrent conditions other than seasonal AR. The primary endpoint of the study is to evaluate the clinical efficacy of LP-003 in the treatment of moderate-to-severe seasonal AR that

is inadequately controlled by standard treatment (total nasal symptom scores (TNSS) during the peak pollen season (PPP)). Secondary endpoints are to evaluate the safety, efficacy (daily nasal symptom and rescue medication treatment scores (DNSMS), daily ocular symptom and rescue medication treatment scores (DNOMS)), PK, and PD of LP-003 for the treatment of seasonal AR.

ABOUT LP-003

LP-003 is an anti-IgE antibody with novel sequencing. LP-003 is targeted to treat allergic diseases, including seasonal AR, CSU, allergic asthma, CRSwNP and food allergy. The primary function of LP-003 is to block free IgE in blood and tissues, and thus inhibiting the occurrence of IgE-driven allergic reactions. LP-003 has the capability to bind free IgE and prohibit those free and excessive IgE from binding to the high-affinity IgE receptor, FcεRI. IgE is the core mechanism driving Type I hypersensitivity. Type I hypersensitivity triggered by allergens in different organs causes seasonal AR, allergic asthma, CSU, food allergy and other allergic diseases. Anti-IgE antibody currently plays a pivotal role in the treatment of a variety of allergic diseases due to its capabilities of achieving cascade of allergic reactions. Anti-IgE therapy has been included in Chinese guidelines for the diagnosis and treatment of seasonal AR and CSU. We have obtained IND approvals and/or initiated clinical trials for LP-003 in China for various indications, including seasonal AR, CSU, allergic asthma, CRSwNP and food allergy.

ABOUT THE COMPANY

The Company is a clinical-stage biopharmaceutical company. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, the Company primarily focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases. The Group has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases.

The Company cannot guarantee that it will be able to develop and/or ultimately market LP-003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, June 12, 2026

As at the date of this announcement, the Board comprises Dr. LIU Heng as the chairman of the Board and executive Director and Dr. SUN Bill Nai-chau and Mr. XIE Ming, as executive Directors, Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Dr. CHEN Kan as non-executive Directors, and Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.